Artelo Biosciences shares rise 10.26% intraday after announcing new peer-reviewed study on intraperitoneal FABP5 administration.

Artelo Biosciences surged 10.26% intraday after announcing the publication of a peer-reviewed study demonstrating the intraperitoneal administration of a novel FABP5-targeting therapy. The study, highlighting the therapeutic potential of this delivery method for addressing fibrotic diseases, underscores the company’s progress in advancing its pipeline and validates its scientific approach. The positive reception of this milestone in the biopharmaceutical sector likely drove the intraday rally, reflecting investor confidence in the company’s research capabilities and future clinical development prospects.